Indeed, this multivariate analysis of our real-world cohort identified a minimal immune signature consisting of a high percentage of activated CD4+ T-lymphocytes and low percentages of CTLA-4+ T-lymphocytes and immature B-lymphocytes that were strongly associated with disease severity and manifested even four to eight weeks after COVID-19. The gene discussed is CTLA4; the disease is COVID-19.